Overview
The purpose of this study is to see if the new study drug, Ziltivekimab, can be used to treat people with cardiovascular disease, chronic kidney disease, and inflammation. The ZEUS study will see if Ziltivekimab can reduce the risk of having cardiovascular events (for example, heart attack and stroke). The term cardiovascular refers to various conditions that affect the heart and blood vessels. These conditions include myocardial infringement (also known as heart attack), cerebrovascular accident (also known as stroke), and peripheral arterial disease (also known as poor circulation). Ziltivekimab is an antibody, which is designed to block the section of IL6 so ziltivekimab can help the body prevent further inflammation.
Description